Infanrix Polio (Poliovirus (Inactivated) Type 3 (Saukett Strain), Pertussis Filamentous Haemagglutinin Adsorbed On A)

The poliovirus component contains inactivated type 3 poliovirus (Saukett strain). When injected, the virus particles cannot cause disease but are recognized by the immune system, prompting the production of neutralising antibodies that protect against future exposure to wild poliovirus.

The dosing schedule for Infanrix Polio is determined by the prescribing healthcare professional based on national immunisation guidelines. Typically, the vaccine is given as a series of intramuscular injections at specific ages in infancy, but the exact timing and number of doses are set by the prescriber.

Data on the use of Infanrix Polio during pregnancy are limited, and the vaccine is generally not recommended for pregnant women unless the potential benefits outweigh any theoretical risks. The vaccine is considered compatible with breastfeeding, but mothers should consult their healthcare provider for personalized advice.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Infanrix Polio is an EU‑licensed, fully adsorbed combination vaccine that includes inactivated poliovirus type 3, diphtheria and tetanus toxoids, and acellular pertussis antigens. Compared with some alternatives, it uses a specific pertussis filamentous haemagglutinin component and a defined poliovirus strain, offering comparable efficacy and a safety profile consistent with other licensed DTaP‑IPV products.

Infanrix Polio must be stored refrigerated at 2 °C to 8 °C. It should be kept in the original packaging to protect from light, must not be frozen, and should not be shaken. Before use, allow the vial to reach room temperature for a short period if required by the label.

The vaccine is administered by a trained healthcare professional as an intramuscular injection, usually into the anterolateral thigh of infants. The injection site is cleaned with an appropriate antiseptic, and the recommended volume is drawn into a sterile syringe before administration.

Serious adverse events are rare but may include anaphylaxis, seizures, Guillain‑Barré syndrome, and prolonged hypotonic‑hyporesponsive episodes. Immediate medical attention is required if signs of a severe allergic reaction (such as difficulty breathing, swelling of the face or throat) or neurological symptoms occur after vaccination.

Infanrix Polio should be avoided in individuals with a known severe allergy to any vaccine component, including the aluminium adjuvant, or in those who have experienced a previous severe reaction to a DTaP‑IPV vaccine. Children with a moderate or severe acute illness should have vaccination postponed until recovery.